The lncRNA, MEG3, which regulates the insulin signaling pathway implicated in the molecular mechanism of T3D, may be a molecular therapeutic target for managing the onset of complications and the advancement of the disease brought on by diabetes and Alzheimer’s disease. This evidence concerns the gene MEG3 and early-onset autosomal dominant Alzheimer disease.